EXAS vs. TWST: A Head-to-Head Stock Comparison

Updated on November 22, 2025

Here’s a clear look at EXAS and TWST, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Symbol	EXAS	TWST
Company Name	Exact Sciences Corporation	Twist Bioscience Corporation
Country	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry	Biotechnology	Biotechnology
Market Capitalization	12.87 billion USD	1.65 billion USD
Exchange	NasdaqCM	NasdaqGS
Listing Date	February 1, 2001	October 31, 2018
Security Type	Common Stock	Common Stock

Historical Performance

This chart compares the performance of EXAS and TWST by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

EXAS vs. TWST: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	EXAS	TWST
5-Day Price Return	0.68%	-13.21%
13-Week Price Return	47.00%	-4.45%
26-Week Price Return	24.89%	-16.79%
52-Week Price Return	32.13%	-36.76%
Month-to-Date Return	3.62%	-18.30%
Year-to-Date Return	19.29%	-42.18%
10-Day Avg. Volume	3.67M	1.88M
3-Month Avg. Volume	2.86M	1.67M
3-Month Volatility	29.23%	67.24%
Beta	1.43	2.21

Profitability

Return on Equity (TTM)

EXAS

-40.39%

Biotechnology Industry

Max: 96.19%
Q3: 12.45%
Median: -16.39%
Q1: -47.43%
Min: -131.19%

EXAS has a negative Return on Equity of -40.39%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

TWST

-18.45%

Biotechnology Industry

Max: 96.19%
Q3: 12.45%
Median: -16.39%
Q1: -47.43%
Min: -131.19%

TWST has a negative Return on Equity of -18.45%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

EXAS vs. TWST: A comparison of their Return on Equity (TTM) against the Biotechnology industry benchmark.

Net Profit Margin (TTM)

EXAS

-32.01%

Biotechnology Industry

Max: 84.13%
Q3: 19.34%
Median: -1.39%
Q1: -117.64%
Min: -296.77%

EXAS has a negative Net Profit Margin of -32.01%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

TWST

-23.51%

Biotechnology Industry

Max: 84.13%
Q3: 19.34%
Median: -1.39%
Q1: -117.64%
Min: -296.77%

TWST has a negative Net Profit Margin of -23.51%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

EXAS vs. TWST: A comparison of their Net Profit Margin (TTM) against the Biotechnology industry benchmark.

Operating Profit Margin (TTM)

EXAS

-32.45%

Biotechnology Industry

Max: 78.85%
Q3: 20.86%
Median: 0.51%
Q1: -128.29%
Min: -315.84%

EXAS has a negative Operating Profit Margin of -32.45%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

TWST

-39.30%

Biotechnology Industry

Max: 78.85%
Q3: 20.86%
Median: 0.51%
Q1: -128.29%
Min: -315.84%

TWST has a negative Operating Profit Margin of -39.30%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

EXAS vs. TWST: A comparison of their Operating Profit Margin (TTM) against the Biotechnology industry benchmark.

Profitability at a Glance

Symbol	EXAS	TWST
Return on Equity (TTM)	-40.39%	-18.45%
Return on Assets (TTM)	-16.91%	-13.84%
Net Profit Margin (TTM)	-32.01%	-23.51%
Operating Profit Margin (TTM)	-32.45%	-39.30%
Gross Profit Margin (TTM)	67.37%	49.24%

Financial Strength

Current Ratio (MRQ)

EXAS

2.72

Biotechnology Industry

Max: 15.83
Q3: 7.97
Median: 4.06
Q1: 2.64
Min: 0.72

EXAS’s Current Ratio of 2.72 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

TWST

3.90

Biotechnology Industry

Max: 15.83
Q3: 7.97
Median: 4.06
Q1: 2.64
Min: 0.72

TWST’s Current Ratio of 3.90 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

EXAS vs. TWST: A comparison of their Current Ratio (MRQ) against the Biotechnology industry benchmark.

Debt-to-Equity Ratio (MRQ)

EXAS

0.94

Biotechnology Industry

Max: 1.27
Q3: 0.62
Median: 0.13
Q1: 0.00
Min: 0.00

EXAS’s leverage is in the upper quartile of the Biotechnology industry, with a Debt-to-Equity Ratio of 0.94. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

TWST

0.00

Biotechnology Industry

Max: 1.27
Q3: 0.62
Median: 0.13
Q1: 0.00
Min: 0.00

TWST’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

EXAS vs. TWST: A comparison of their Debt-to-Equity Ratio (MRQ) against the Biotechnology industry benchmark.

Interest Coverage Ratio (TTM)

EXAS

-15.18

Biotechnology Industry

Max: 72.37
Q3: 1.71
Median: -15.18
Q1: -65.75
Min: -166.46

EXAS has a negative Interest Coverage Ratio of -15.18. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

TWST

-235.67

Biotechnology Industry

Max: 72.37
Q3: 1.71
Median: -15.18
Q1: -65.75
Min: -166.46

TWST has a negative Interest Coverage Ratio of -235.67. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

EXAS vs. TWST: A comparison of their Interest Coverage Ratio (TTM) against the Biotechnology industry benchmark.

Financial Strength at a Glance

Symbol	EXAS	TWST
Current Ratio (MRQ)	2.72	3.90
Quick Ratio (MRQ)	2.24	3.45
Debt-to-Equity Ratio (MRQ)	0.94	0.00
Interest Coverage Ratio (TTM)	-15.18	-235.67

Growth

Revenue Growth

EXAS vs. TWST: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

EXAS vs. TWST: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

EXAS

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

EXAS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

TWST

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TWST currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

EXAS vs. TWST: A comparison of their Dividend Yield (TTM) against the Biotechnology industry benchmark.

Dividend Payout Ratio (TTM)

EXAS

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

EXAS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

TWST

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TWST has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

EXAS vs. TWST: A comparison of their Dividend Payout Ratio (TTM) against the Biotechnology industry benchmark.

Dividend at a Glance

Symbol	EXAS	TWST
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

Price-to-Earnings Ratio (TTM)

EXAS

Biotechnology Industry

Max: 115.91
Q3: 56.76
Median: 21.80
Q1: 15.79
Min: 4.51

P/E Ratio data for EXAS is currently unavailable.

TWST

Biotechnology Industry

Max: 115.91
Q3: 56.76
Median: 21.80
Q1: 15.79
Min: 4.51

P/E Ratio data for TWST is currently unavailable.

EXAS vs. TWST: A comparison of their Price-to-Earnings Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Sales Ratio (TTM)

EXAS

4.12

Biotechnology Industry

Max: 58.56
Q3: 29.31
Median: 8.30
Q1: 4.89
Min: 0.86

In the lower quartile for the Biotechnology industry, EXAS’s P/S Ratio of 4.12 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

TWST

4.34

Biotechnology Industry

Max: 58.56
Q3: 29.31
Median: 8.30
Q1: 4.89
Min: 0.86

In the lower quartile for the Biotechnology industry, TWST’s P/S Ratio of 4.34 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

EXAS vs. TWST: A comparison of their Price-to-Sales Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Book Ratio (MRQ)

EXAS

4.14

Biotechnology Industry

Max: 17.92
Q3: 10.38
Median: 4.78
Q1: 2.85
Min: 0.78

EXAS’s P/B Ratio of 4.14 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

TWST

4.61

Biotechnology Industry

Max: 17.92
Q3: 10.38
Median: 4.78
Q1: 2.85
Min: 0.78

TWST’s P/B Ratio of 4.61 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

EXAS vs. TWST: A comparison of their Price-to-Book Ratio (MRQ) against the Biotechnology industry benchmark.

Valuation at a Glance

Symbol	EXAS	TWST
Price-to-Earnings Ratio (TTM)	--	--
Price-to-Sales Ratio (TTM)	4.12	4.34
Price-to-Book Ratio (MRQ)	4.14	4.61
Price-to-Free Cash Flow Ratio (TTM)	51.33	--